ASCO Annual Meeting | Conference

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

June 9th 2015

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Stefani Spranger on Î²-Catenin Signaling and Overcoming Immunotherapy Resistance

June 8th 2015

Stefani Spranger, PhD, University Chicago Melanoma Intrinsic Î²-Catenin Committee, discusses the effect of melanoma intrinsic Î²-catenin signaling on immune exclusion and resistance to immunotherapies.

Triplet Therapy Effective in BRAF-mutant mCRC

June 8th 2015

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Dr. Mesa on Pacritinib for Myelofibrosis

June 8th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Lenvatinib Plus Everolimus Improves Survival in mRCC

June 5th 2015

The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

June 5th 2015

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

June 5th 2015

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dr. Manish Shah on the METGastric Study

June 4th 2015

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma

June 3rd 2015

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

Carfilzomib Tops Bortezomib in Relapsed Myeloma

June 3rd 2015

Progression-free survival in relapsed myeloma doubled among patients treated with carfilzomib, rather than bortezomib, in combination with dexamethasone, a randomized trial showed.

Dr. Brufsky on Anastrozole Versus Tamoxifen in DCIS

June 3rd 2015

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

Dr. Cristofanilli on the PALOMA3 Trial for Breast Cancer

June 3rd 2015

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

PD-1/PD-L1 Inhibitors Safe, Effective in Advanced Ovarian Cancer

June 3rd 2015

Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.

Trabectedin Extends PFS in Phase III Soft Tissue Sarcoma Study

June 3rd 2015

Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer

June 2nd 2015

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Dr. Socinski on Nivolumab in NSCLC

June 2nd 2015

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).

Dr. Wolchock on the Phase III CheckMate-067 Melanoma Findings

June 2nd 2015

Jedd Wolchok, MD, PhD, chief, melanoma and immunotherapeutics service and Lloyd J. Old Chair for clinical investigation at Memorial Sloan Kettering Cancer Center, discusses the findings of the Phase III CheckMate-067 trial.

Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study

June 2nd 2015

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

Dr. Spira on Atezolizumab in the POPLAR Study for NSCLC

June 2nd 2015

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).